Pin‐point targeting of the key modulator in LC like epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase, or ROS proto‐oncogene‐1 (ROS1) are promising features of some tumor‐specific therapeutic agents. Here, EGFR is linked to neoplasm.